According to an interim analysis, its own vaccine candidate CVnCoV only achieved a preliminary effectiveness of 47 percent against corona disease “of any severity” and thus did not meet the specified statistical success criteria, according to the company from Tübingen in Germany on Thursday night.
The stock market price plummeted in after-hours US trading on Wednesday by more than half. For a long time, Curevac had been considered one of the beacons of hope in the highly competitive international race for the approval of the first corona vaccines. But while vaccines have been administered by numerous competitors worldwide for months, the biotech company continues to collect data – and recently put off shareholders and observers time and again. The Curevac vaccine candidate has long been in the final and therefore approval-relevant 2b / 3 study phase.
Until the beginning of June it had been said that the company expected – depending on the clinical study data – the approval of its vaccine candidate in the EU at least for the second quarter. But shortly afterwards it was announced that the proceedings would be further delayed. Curevac CEO Franz-Werner Haas announced that they had hoped for stronger results in the interim analysis. But continue the current study until the final analysis. “The final effectiveness could still change.”
The European Union has secured up to 405 million doses of the Curevac vaccine. In Germany, the Ministry of Health recently announced that the drug would only be included in the planning for the vaccination campaign after approval. In this quarter the delivery of 1.4 million vaccine doses was canceled. The German Chancellor Angela Merkel defended the company the previous week because of the delays.
David William is a talented author who has made a name for himself in the world of writing. He is a professional author who writes on a wide range of topics, from general interest to opinion news. David is currently working as a writer at 24 hours worlds where he brings his unique perspective and in-depth research to his articles, making them both informative and engaging.
